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OPEN
ORIGINAL ARTICLE
Glucagon-like peptide 1 receptor activation regulates cocaine
actions and dopamine homeostasis in the lateral septum by
decreasing arachidonic acid levels
IA Reddy1,12, JA Pino2,3,12, P Weikop4,5, N Osses2, G Sørensen4,5, T Bering4, C Valle6, RJ Bluett1,7, K Erreger8, G Wortwein4,9, JG Reyes2,
D Graham10, GD Stanwood10, TA Hackett1,11, S Patel7, A Fink-Jensen4,5, GE Torres3,13 and A Galli1,8,13
Agonism of the glucagon-like peptide 1 (GLP-1) receptor (GLP-1R) has been effective at treating aspects of addictive behavior for a
number of abused substances, including cocaine. However, the molecular mechanisms and brain circuits underlying the
therapeutic effects of GLP-1R signaling on cocaine actions remain elusive. Recent evidence has revealed that endogenous signaling
at the GLP-1R within the forebrain lateral septum (LS) acts to reduce cocaine-induced locomotion and cocaine conditioned place
preference, both considered dopamine (DA)-associated behaviors. DA terminals project from the ventral tegmental area to the LS
and express the DA transporter (DAT). Cocaine acts by altering DA bioavailability by targeting the DAT. Therefore, GLP-1R signaling
might exert effects on DAT to account for its regulation of cocaine-induced behaviors. We show that the GLP-1R is highly expressed
within the LS. GLP-1, in LS slices, signiﬁcantly enhances DAT surface expression and DAT function. Exenatide (Ex-4), a long-lasting
synthetic analog of GLP-1 abolished cocaine-induced elevation of DA. Interestingly, acute administration of Ex-4 reduces septal
expression of the retrograde messenger 2-arachidonylglycerol (2-AG), as well as a product of its presynaptic degradation,
arachidonic acid (AA). Notably, AA reduces septal DAT function pointing to AA as a novel regulator of central DA homeostasis. We
further show that AA oxidation product γ-ketoaldehyde (γ-KA) forms adducts with the DAT and reduces DAT plasma membrane
expression and function. These results support a mechanism in which postsynaptic septal GLP-1R activation regulates 2-AG levels to
alter presynaptic DA homeostasis and cocaine actions through AA.
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INTRODUCTION
Cocaine addiction is a highly prevalent disorder characterized by
continued drug use in spite of negative consequences. Despite
the harmful effects of cocaine, the development of pharma-
cotherapies to treat cocaine addiction has been slow. This is
because modulators of addictive behavior are limited and we lack
a comprehensive understanding of their mechanisms. Starting
with the discovery that glucagon-like peptide 1 (GLP-1) regulates
amphetamine-induced locomotion,1 GLP-1 receptor (GLP-1R)
agonism has been shown to reduce the rewarding properties of
cocaine and other drugs of abuse in rodents.2–4
GLP-1 is both a hormone produced by L cells of the intestine
and a neuropeptide produced by the nucleus of the tractus
solitarius.5,6 Notably, GLP-1 synthetic analogs are already
approved to treat type 2 diabetes and obesity in humans.7,8
These synthetic derivatives have a greatly extended half-life over
endogenous GLP-1.5,7 As such, they remain in circulation long
enough to cross the blood–brain barrier.9 The importance of the
brain bioavailability of GLP-1 analogs is underscored by the
prominent expression of the GLP-1R within the brain.10 Ex-4 is one
such synthetic GLP-1 analog that has been used extensively to
demonstrate that GLP-1R activation reduces the preference and
actions of cocaine, amphetamine, alcohol and nicotine.1,2,11,12–17
Importantly, the GLP-1R 168Ser allele has been associated with
increased measures of alcohol self-administration in humans.17
These data suggest that GLP-1R signaling might regulate common
mechanisms within the brain’s reward system.
The neurotransmitter dopamine (DA) underlies the rewarding
properties of drugs of abuse, as well as natural rewards.18 It is
released at DA terminals during drug intake and in anticipation of
the consumption of drugs.18,19 We therefore hypothesized that
the effects of GLP-1R stimulation on cocaine reward would occur
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at DA nodes exhibiting GLP-1R signaling. One such node is found
within the forebrain lateral septum (LS). The LS possesses a high
concentration of GLP-1Rs and contains DA projections.10 In
addition, the LS has historically been linked to reward; it was
identiﬁed by Olds and Milner20 as a potent site of electrical self-
stimulation in rats.20 Since then, several studies have found that
the LS is fundamental to the rewarding properties of drugs of
abuse.3,21–23 Most notably, the Aston-Jones group has found that
the LS is an important relay center between the hippocampus and
the ventral tegmental area (VTA) for information about cocaine–
context associations and that the LS is necessary for the formation
of cocaine conditioned place preference (CPP). 22,23
Recently, Harasta et al.3 found that endogenous signaling
through the GLP-1R in the LS acts to dampen cocaine-induced
locomotion and cocaine CPP, both considered DA-associated
behaviors.3 In the current study, we sought to determine the
mechanism by which GLP-1R stimulation modulates septal DA
homeostasis and the actions of cocaine. Cocaine blocks DA
reuptake via the DA transporter (DAT), resulting in high levels of
synaptic DA. Here we demonstrate that GLP-1R stimulation
inhibits the ability of cocaine to increase extracellular DA levels.
This phenomenon is associated with increased DAT surface
expression and function mediated by a reduction in endocanna-
binoid and arachidonic acid (AA) levels in the LS. These ﬁndings
reveal a novel mechanism of GLP-1R action in brain and provide a
more comprehensive understanding of how emerging GLP-1R-
targeted therapies affect signaling in the brain.
MATERIALS AND METHODS
Animals
Male NMRI mice (Taconic, Lille Skensved, Denmark) were used for
microdialysis and c-fos experiments.4 Sprague Dawley rats, weighing
320–345 g, were also used for the study (Taconic). All other in vivo
experiments used adult male C57BL/6 mice from Jackson Laboratories
(Farmington, CT, USA) or bred internally at the Vanderbilt University
(Nashville, TN, USA). All the animals were kept at room temperature in a
12 h light/dark cycle with free access to food and water. All the
experiments were performed during the light cycle. For immunohisto-
chemical characterization of GLP-1R localization, bacterial artiﬁcial
chromosome transgenic mice containing a ﬂuorescent reporter expressed
in GLP-1R-expressing cells were generated as described in Supplementary
Information. All the experiments were in accordance with directives of
‘Principles of Laboratory Animal Care’ (NIH publication No. 85–23) and
approved by either the Danish Experimental Animal Inspectorate and the
council of the European Communities or the Vanderbilt Institutional
Animal Care and Use Committee.
Drugs and materials
The suppliers for all chemicals not otherwise identiﬁed can be found in the
Supplementary Information.
Immunohistochemistry for DAT and mApple
The brains from GLP-1R bacterial artiﬁcial chromosome transgenic mice
were extracted, post-ﬁxed overnight in PFA and sectioned by vibratome
(75 μm). The sections were immunostained and imaged as described in the
Supplementary Information.
High-speed chronoamperometry
The slices containing LS (300 μm) were prepared and chronoamperometry
performed as previously described.24 High KCl artiﬁcial cerebrospinal ﬂuid
(with 30 mM KCl, 97.5 mM NaCl) was applied to the bath for 2 min to induce
DA release. The oxidative signal measured in the slices is attributable to DA
as the reduction/oxidation charge ratio is in the range 0.6–1.0.
c-fos expression
The procedure for c-fos IHC is as previously described.25 Brieﬂy, the coronal
brain sections (15 μm) were cut through septum using a cryostat. Synthetic
oligonucleotide DNA probes (DNATechnology, Aarhus, Denmark) were
used for the visualization of c-fos mRNA by autoradiography. The probe
sequence was 5′-CGGGCAGTGGCACGTCTGGATGCCGGCTGCCTTGCCTTCTC
TGACTGC-3′.
In vivo microdialysis in mice
Microdialysis was performed as described previously4 with few modiﬁca-
tions. The dialysis probe was positioned in LS, anteroposterior: 0.5 mm,
mediolateral: 0.3 mm relative to the bregma and dorsoventral: − 2.2 mm
relative to skull surface.26 The microdialysis probe was perfused at a rate of
0.9 μl min− 1 with artiﬁcial cerebrospinal ﬂuid. The ﬁrst two 30-min samples
were discarded to obtain stable basal values. Hereafter, two 30-min
fractions were collected to establish baseline DA levels. Subsequently, the
mice were injected with Ex-4 or vehicle, and three 30-min fractions were
collected. The mice were then subjected to local perfusion with cocaine
(50 μM) for 30 min and ﬁve 30-min fractions were collected. All the
fractions were assayed immediately after collection using high-
performance liquid chromatography with electrochemical detection.27
Ex vivo slice protein biotinylation assay
The procedure for biotinylation of live brain slices has been validated and
was performed at 28 °C as described previously.28
Ex vivo slice [3H]DA transport assay
The slices were obtained as described above and allowed to recover (⩾1 h
at 28 °C) with continuous oxygenation. Following the recovery, the slices
were treated with the drug (that is, GLP-1) for 10 min followed by the
application of 50 nM [3H]DA for 10 min with the drug still present at 28 °C.
When Ex-9 was used, the slices were pretreated with Ex-9 for 10 min before
the addition of drug/vehicle. Total protein was taken, and the samples
were processed for protein concentration using a Bio-Rad (Philadelphia,
PA, USA) protein assay and spectrometry at 595 nm. Equivalent volumes of
the sample were added to 3 ml of scintillation ﬂuid (Ecoscint H, National
Diagnostics, Atlanta, GA, USA) and radioactive counts were measured by
scintillation counter. [3H]DA was divided by protein and normalized to
average control uptake from paired vehicle-treated slices from the same
animal. The uptake protocol and DAT speciﬁcity were validated in slices
treated with DAT blocker GBR-12909 (Sigma Aldrich, St. Louis, MO, USA),
which blocked uptake in LS by 58.2% (t(5) = 11.97; Po0.0001 by Student’s
t-test; n= 6).
2-AG and AA measurements
The mice were injected with Ex-4 or vehicle (intraperitoneally) 30 min
before being killed. The mice were rapidly decapitated and the brains were
obtained and blocked to obtain DS and LS punches. Punches were quickly
placed into Eppendorf tubes on dry ice and stored at − 80 °C until use. The
samples were homogenized in methanol and centrifuged; water was
added to the supernatant for a ﬁnal ratio of 70:30 methanol:water. Liquid
chromatography/mass spectrometry was performed as previously
described.29 Following liquid chromatography/mass spectrometry, excess
methanol was suctioned off the pellets. The pellets were resuspended and
processed for protein concentration using a Bio-Rad protein assay and
spectrometry at 595 nm.
Cell culture
Rat pheochromocytoma cells (PC12) were obtained from the American
Type Culture Collection (Manassas, VA, USA), and were cultured in
Dulbecco’s Modiﬁed Eagle’s medium supplemented with 6% fetal bovine
serum (heat inactivated), 6% horse serum (heat inactivated), 1 mM
glutamine, 100U ml− 1 penicillin and 100 μg ml− 1 streptomycin at 37 °C
in a humidiﬁed 5% CO2 incubator.
30 The PC12 cells overexpressing human
DAT fused to GFP (hDAT cells) were stably transfected with the plasmid
peGFP-C2-hDAT using Lipofectamine 2000 and were cultured under the
same conditions. Krebs–Henseleit buffer was used (144 mM NaCl, 4.2 mM
KCl, 1.6 mM MgCl2, 1.6 mM KH2PO4, 10 mM HEPES, pH 7.4) and Fe
+3
(197 μM)/ascorbate (19.7 mM) solutions were prepared in Krebs–Henseleit
buffer. In some cases, salicylamine, a γ-KA scavenger, was added to the
culture media and preincubated with the cells for 1 h at 37 °C before
further treatments. The cell viability was measured using Trypan blue
staining.
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PC12 transport assays
The DAT-mediated uptake of DA in PC12 cells overexpressing a GFP-
tagged DAT (hDAT) has been described previously.31
Cell surface biotinylation in hDAT cells
The cell surface biotinylation was performed as described by Egaña et al.31
with some modiﬁcations.
Immunoprecipitations
Immunoprecipitations were performed using 1 mg total protein. To
immunoprecipitate DAT-GFP, the cell homogenates were incubated
overnight at 4 °C with a monoclonal anti-GFP antibody (G-6539, 1:100),
followed by the addition of 50 μl of a mixture of protein A and protein G
Sepharose beads (2 h at 4 °C in rotatory shaker). The immunoprecipitated
proteins were recovered by centrifugation at 14 000 g for 2 min (4 °C),
washed with ice-cold buffer D, and resuspended in protein sample buffer
containing βME. The proteins were separated by SDS-polyacrylamide gel
electrophoresis and transferred to PVDF membranes before incubation
with an antibody against γ-KA-lysil adduct (neuroketals antibody, C-17,
1:400) and anti-DAT (MAB369, 1:1000).
Analyses
The data are presented as means± s.e.m. The data were examined with
Student’s t-test for comparisons of only two data sets and one-way or two-
way analysis of variance for comparisons of multiple groups, followed by
Tukey’s- or Bonferroni-corrected comparisons. In ex vivo [3H]DA uptake
experiments, samples with low protein content (o6 μg ml− 1) were
excluded from the analysis (n= 1). Optical density of bands was
determined using Image J software. The statistical analysis was performed
with GraphPad Prism software, version 5.02 (GraphPad Software, San
Diego, CA, USA). A P-value o0.05 deﬁned the statistical signiﬁcance.
Figure 1. The glucagon-like peptide 1 receptor (GLP-1R) is highly expressed in the lateral septum (LS) where GLP-1R agonists block cocaine-
induced dopamine (DA) in vivo. (a-c) Cells expressing the GLP-1R (white in a, red in c) and terminals expressing dopamine transporter (DAT;
white in b, green in c) in rostral LS (GLP-1R in a, DAT in b, merge in c). Confocal images in z stack through 13 planes taken with a × 10
objective. (d-f) Cells expressing the GLP-1R (white in d, red in f) and terminals expressing DAT (white in e, green in f) in caudal LS (GLP-1R in d,
DAT in e, merge in f). Confocal images in z stack through 14 planes taken with a × 10 objective. (g) DA release induced by 30 mM KCl
(representative of n= 3) in section from the caudal LS. Approximate site of recording is demarcated by * in f. Ld, laterodorsal tegmental
nucleus; LSd, dorsal LS; LSi, intermediate LS; LSv, ventral LS; MS, medial septum; SHi, septohippocampal nucleus. Dotted lines delineate region
boundaries.26 Scale bars, 100 μm. (h) Representative c-fos expression in the LS 30 min following vehicle (top) or Ex-4 (30 μg kg− 1,
intraperitoneally, bottom) injection. Dotted box includes the LS. (i) Quantiﬁcation of optical density analysis of c-fos autoradiographs in LS
(t(14)= 3.26; **Po0.01 by Student’s t-test; n= 8). (j) Cocaine (50 μM) greatly increased septal DA levels in mice pretreated with saline
(intraperitoneally, solid circles). This cocaine-induced DA increase is signiﬁcantly diminished in mice pretreated with Ex-4 (1 μg kg− 1
intraperitoneally, solid triangles; 30 μg kg− 1 intraperitoneally, solid squares). Extracellular concentrations of DA are expressed as the
percentage of basal levels in two fractions collected before the intervention; signiﬁcant analysis of variance. Open symbols indicate
signiﬁcance by post hoc test where Po0.001 at 150 min and Po0.05 at 120 min; n= 5–6 per group.
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The methods for Supplementary Figures can be found in the
Supplementary Information.
RESULTS
GLP-1R-expressing neurons are juxtaposed to DA terminals in
the LS
The GLP-1R is highly expressed within the LS,10 a brain region in
which DAT-expressing DA terminals reside.32 Here, to the best of
our knowledge, we ﬁrst describe their proximity and anatomical
distribution in this region (Figure 1). To this end, we generated a
transgenic mouse expressing a bacterial artiﬁcial chromosome for
the protein mApple under the control of the promoter for the
GLP-1R. The mApple signal was ampliﬁed by immunostaining
(Figures 1a, c, d and f) and DAT was labeled in parallel (Figures 1b,
c, e and f). Within the rostral LS (Figures 1a–c), the DA terminals
are found medially in the intermediate LS subregion (LSi), directly
adjacent to GLP-1R-expressing cells found mostly in the dorsal LSi.
We observed visible overlap between these cell bodies/projec-
tions and DA terminals. Within the caudal LS (Figures 1d–f), there
is similar evidence for this anatomical overlap. The DA terminals
are labeled as two strips extending dorsomedially to ventrolat-
erally in the LSi. The GLP-1R-expressing cells are also found in the
caudal LSi, but the cell bodies additionally extend further into the
more medial laterodorsal tegmental area. Importantly, we show
that DA terminals within this region release DA: superfusing LS
slices with an artiﬁcial cerebrospinal ﬂuid solution containing high
[K+] causes DA release as recorded by high-speed chronoampero-
metry (Figure 1g; approximate electrode placement is denoted by
* in Figure 1f). The use of mApple for identifying GLP-1R-
expressing neurons was validated by in situ hybridization
(Supplementary Figure 1).
Systemic administration of a GLP-1R agonist reduces cocaine-
induced DA elevation and c-fos expression in the LS
We next tested whether a therapeutically relevant administration
(that is, systemic administration) of Ex-4 was capable of altering
neuronal activity in the LS. We ﬁrst evaluated the effect of Ex-4 on
the activation of septal neurons by measuring c-fos expression. Ex-
4 administration (intraperitoneally) 30 min before killing
decreased basal c-fos gene expression by in situ hybridization
relative to vehicle-treated mice (Figures 1h and i). This result
indicates that systemic administration of Ex-4 alters neuronal
activity in the LS.
The psychogenic and addictive properties of cocaine are
mediated, at least in part, through the blockade of DAT-
mediated DA reuptake and an increase in extracellular DA.33,34
Therefore, signaling pathways able to modulate or diminish this
DA increase offer enormous therapeutic potential. We determined
the effect of systemic Ex-4 on local cocaine-induced changes in
DA homeostasis in vivo within the LS, as measured by
microdialysis in freely moving mice. The perfusion of cocaine
Figure 2. Local activation of the glucagon-like peptide 1 receptor (GLP-1R) promotes septal dopamine transporter (DAT) membrane
expression and [3H]DA uptake. (a) Representative immunoblot of surface and total DAT following slice treatment with vehicle (artiﬁcial
cerebrospinal ﬂuid, aCSF) or 1 nM GLP-1. (b) Ratio of DAT surface expression in GLP-1-treated ex vivo septal slices as percentage of average
vehicle values (t(3)= 10.12; **Po0.01 by Student’s t-test; n= 4). The slices were treated with 1 nM GLP-1 for 20 min. (c) [3H]DA uptake in the LS
from ex vivo slice preparation following 20 min treatment with vehicle (aCSF) or 10 nM GLP-1. Uptake was signiﬁcantly elevated (t(4)= 2.35;
*Po0.05 by Student’s t-test; n= 5). (d) Pretreatment with 100 nM Ex-9 for 10 min blocks the increase in [3H]DA uptake following treatment with
10 nM GLP-1 (t(3)= 1.047; P= 0.19 by Student’s t-test; n= 4).
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through the microdialysis probe increased septal DA ~ 5-fold
(Figure 1j; F(9,49) = 2.73, P=0.014 by analysis of variance). Systemic
pretreatment with Ex-4 (intraperitoneally) 90 min prior impaired
the cocaine’s ability to signiﬁcantly increase extracellular DA. These
results were paralleled in rats (Supplementary Figure 2A), demon-
strating across species that GLP-1R activation diminishes the
cocaine’s ability to increase extracellular DA in the LS.
Local GLP-1R signaling blocks cocaine-induced elevation in DA,
promotes septal DAT membrane expression and increases DA
uptake
We next sought to determine whether local GLP-1R activation
could account for observed systemic effects of Ex-4 on the LS. Ex-4
or vehicle was perfused through the microdialysis probe
concurrently with cocaine (Supplementary Figure 2B). The local
administration of Ex-4 impaired the ability of cocaine to increase
extracellular DA levels. This ﬁnding further highlights the role of
septal GLP-1Rs in modulating cocaine’s ability to enhance DA
function.
Multiple mechanisms could explain how local GLP-1R signaling
impairs cocaine-induced increases in extracellular DA in the LS.
However, DAT-mediated DA reuptake is the primary mechanism
regulating extracellular DA levels,35 a process dynamically
regulated by DAT plasma membrane expression.36–40 Notably,
DAT expression is inversely proportional to the ability of cocaine
to cause its behavioral effects.41,42 Therefore, we hypothesized
that GLP-1R signaling regulates DA homeostasis in the LS, as well
Figure 3. Treatment of mice with Ex-4 reduces septal arachidonic acid (AA) levels and AA is a strong modulator of dopamine transporter (DAT)
function in lateral septum (LS). (a) Ex-4 (2.4 μg kg− 1, intraperitoneally) administered in vivo 30 min before killing resulted in lower levels of
septal 2-AG (t(11)= 2.62; *Po0.05 by Student’s t-test; n= 6–7). (b) Exenatide (Ex-4; 2.4 μg kg− 1, intraperitoneally) administered 30 min before
death reduces levels of septal AA (t(10)= 5.018; ***Po0.001 by Student’s t-test; n= 6). (c) Eighty micromolar AA applied for 20 min to slices
containing the LS reduces [3H]DA uptake to 42% of vehicle (dimethyl sulfoxide)-treated slices (t(3)= 2.59; *Po0.05 by Student’s t-test; n= 4).
(d) [3H]DA uptake kinetics in human DAT (hDAT) cells treated either with vehicle (open circles) or Fe+3/Asc (open triangles) or with 40 μM AA
for 1 h at 37 °C in absence (gray squares) or presence of Fe+3/Asc (gray triangles). The kinetic parameters (e) Vmax and (f) Km were obtained
from the Michaelis–Menten ﬁt to the inﬂux of [3H]DA. Each value represents mean± s.e.m. of ⩾ three independent experiments. *Po0.05,
****Po0.001, ##Po0.01 and &&Po0.01 indicate signiﬁcant differences between vehicle (Veh) and AA, Veh and Fe+3/Asc+AA, AA and Fe+3/Asc
+AA and Fe+3/Asc and Fe+3/Asc+AA, respectively. Signiﬁcant analysis of variance followed by post hoc tests.
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as cocaine’s ability to increase extracellular DA, by controlling DAT
surface expression. In support of this mechanism, GLP-1 applica-
tion increased surface levels of DAT as measured by LS slice
biotinylation43 (Figures 2a and b). To determine whether the
elevation of DAT surface expression translated to functional
changes in DAT activity, we measured uptake of [3H]DA in septal
slices treated with GLP-1. GLP-1 signiﬁcantly increased DA uptake
(Figure 2c). This increase was speciﬁc to GLP-1R signaling, as
demonstrated by its blockade by the selective GLP-1R antagonist,
exendin-(9–39)-amide (Ex-9; Figure 2d).44 Ex-9 alone had no
signiﬁcant effect (91%±13%; t(3) = 0.6749; P= 0.55 by Student’s t-
test; n= 4). These studies were performed in slices in which only
the local circuits are intact; therefore, we can assume that our
observations were the result of local GLP-1R stimulation and not
the result of feed-forward circuit-level changes. Together, these
data demonstrate that GLP-1R signaling increases both DAT
expression at the plasma membrane and DA uptake, suggesting
that GLP-1R signaling might regulate cocaine actions in the LS
through DAT-dependent mechanisms.
Ex-4 reduces levels of the retrograde messenger, 2-AG, and lowers
levels of AA in the LS
Our ﬁndings thus far suggest that septal GLP-1R agonism affects
DAT expression and function locally. However, the GLP-1R is
predominantly expressed postsynaptically (Figure 1 and
Supplementary Figure 1), whereas the DAT is located on
presynaptic DA terminals (Figure 1). This raised the possibility
that GLP-1R signaling regulates DAT function through a retrograde
signal. 2-AG is a well-established endogenous cannabinoid
retrograde messenger whose signaling has been shown to modify
reward and feeding.45–48 Of note, cannabinoid CB1 receptor
antagonists, which decrease 2-AG signaling, have been shown to
decrease cocaine reward.49 2-AG is synthesized postsynaptically,
but degraded into free AA in presynaptic axon terminals. Indeed,
2-AG hydrolysis via monoacylglycerol lipase is the primary
mechanism for free AA generation in the central nervous
system.50 Importantly, AA impairs DAT-mediated DA uptake.51–53
Thus we sought to determine whether GLP-1R activation
modulates 2-AG-AA signaling. To this end, mice were injected
with Ex-4 (intraperitoneally) 30 min prior to death, and the LS was
punched and analyzed by mass spectrometry for 2-AG and free AA
levels.50 We found that Ex-4 signiﬁcantly reduced both 2-AG and
AA levels in the LS (Figures 3a and b), pointing towards reduced
endocannabinoid metabolism in the LS. This phenomenon was
not observed in the dorsal striatum (DS), where DAT is expressed
in high quantities but GLP-1R-expressing cells are only sparsely
distributed (Supplementary Figure 3). These data demonstrate
region-speciﬁc regulation by GLP-1R signaling of 2-AG levels and
its metabolism.
AA reduces DA uptake and DAT surface expression
Among its functions as a signaling molecule, AA has been
previously shown to impair DAT-mediated DA uptake.51–53
Consistent with ﬁndings from heterologous cell lines and striatal
synaptosomes,51–53 we ﬁrst demonstrated that AA application to
LS slices signiﬁcantly reduced DA uptake (Figure 3c).
Although we have established that AA inhibits DAT function in
the LS, the mechanism(s) responsible for this effect are unknown.
To deﬁne these molecular mechanisms, we adopted PC12 cells
stably transfected with the human DAT (hDAT cells). The PC12
cells contain vesicles capable of neurotransmitter release.54 These
vesicles hold catecholamines (mostly DA) and as such they were
suitable for our molecular studies. The incubation of hDAT cells
with AA alone decreased the DAT maximal velocity (Vmax) to 69%
of control condition (Figures 3d and e). Notably, psychostimulants
are known to induce oxidative stress,55–57 whereas GLP-1R
signaling, which reduces AA levels, is known to reduce it.58 Thus,
we further explored mechanistically the interplay between
oxidative stress and AA levels in terms of DAT function. Here,
we treated hDAT cells with AA along with an oxidizing solution
containing Fe+3 (197 μM) plus ascorbate (19.7 mM, Fe+3/Asc;
Figures 3d–f). Importantly, Fe+3/Asc induces the lipid peroxidation
of AA, a process that produces reactive species capable of
modifying protein structure and function.59–62 Notably, DAT is
highly susceptible to oxidant injury.63–65 We thus posited that AA
might exhibit greater inhibitory effects under oxidative conditions.
Indeed, a greater decrease in Vmax to 34% of control was
obtained when AA was applied in the presence of Fe+3/Asc
(Figures 3d and e; See also Supplementary Figure 4 for validation
of oxidizing conditions and cell viability). However, when
hDAT cells were incubated with Fe+3/Asc alone, there were no
signiﬁcant changes in DAT activity (Figures 3d and e). These
results show that in the presence of AA, there is a signiﬁcant
reduction in DAT function under both oxidizing and non-oxidizing
conditions. Notably, a greater loss of function was observed under
oxidizing conditions, which also affects DAT’s apparent afﬁnity for
DA (Figure 3f).
DAT plasma membrane trafﬁcking is a key regulator of DA
transport capacity.66,67 Therefore, the effect of AA on DAT function
could be explained by the changes in the cell surface expression.
Our results indicate that in hDAT cells, AA, under both oxidative
and non-oxidative conditions, decreases signiﬁcantly and to the
same extent plasma membrane DAT (Figures 4a and b) as
determined by biotinylation. Therefore, the decrease in DAT
function induced by AA alone parallels the decreased transport
Figure 4. Arachidonic acid (AA) decreases dopamine transporter
(DAT) cell surface expression in human DAT (hDAT) cells. (a) Cell
surface biotinylation and immunoblots for DAT using anti-DAT in
extracts from hDAT cells treated with AA (40 μM) for 1 h at 37 °C in
the absence or presence of Fe+3/Asc. (b) Results expressed as the
ratio of optical density between biotinylated (surface) and total DAT
signals for each experimental condition. Each value represents
mean ± s.e.m. of ⩾ three independent experiments. *Po0.05
indicates signiﬁcant differences with respect to vehicle condition
(0.1% ethanol in Krebs–Henseleit buffer). Signiﬁcant analysis of
variance followed by post hoc tests.
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capacity induced by AA (Figure 3). These data also point to
additional mechanisms promoted in terms of DAT function by
oxidative stress.
AA oxidative product, γ-KA, forms a complex with DAT and
regulates its function
The oxidation of AA (mediated by free radicals and other reactive
oxygen/nitrogen species) yields a series of prostaglandin H2
isomers that rearrange to their corresponding γ-ketoaldehydes (γ-
KAs), also named isoketals. These γ-KAs react rapidly with lysine
residues forming stable adducts, which can modulate the activity
of proteins.59–62 At the plasma membrane, DAT localizes to
microdomains including lipid rafts. Lipid rafts are regions highly
enriched in phospholipids containing AA, and DAT localization to
lipid rafts has been associated with regulation of DAT function and
trafﬁcking.68–70 Therefore, we determined whether posttransla-
tional modiﬁcations of DAT by γ-KAs are associated with changes
in DAT function.
To determine whether DAT is a target of AA oxidative products
(for example, γ-KAs) and whether this interaction is relevant for its
function, we conducted experiments using synthetic isoketals
(IsoK). The hDAT cells were incubated with IsoK or vehicle for 1 h
at 37 °C and cell extracts were used for immunoprecipitation
experiments. We observed a signiﬁcant increase (78%) in the
amount of isoketal adducts that co-immunoprecipitated with DAT
compared with the control condition (Figures 5a and b).
Importantly, incubation with IsoK resulted in a 59% decrease in
function compared with vehicle control (Figures 5c and d), with no
change in Km (Figure 5e). Furthermore, we evaluated the effects
of salicylamine, a selective scavenger of γ-KA, on DA uptake
(Figure 5f). In the presence of salicylamine, there were no
signiﬁcant changes in Vmax (Figure 5g) or Km (Figure 5h) when
cells were treated with AA under non-oxidative or oxidative
conditions with respect to the control condition. This is in contrast
to our earlier results in the absence of salicylamine (Figures 3d and
e), suggesting that the ability to form γ-KA-DAT adducts is
necessary for AA to impair DAT function. Importantly, our ﬁndings
demonstrate that DAT is a target of AA oxidative products, and
that this interaction has profound functional implications.
DISCUSSION
Since the discovery that the LS is a potent site of electrical self-
stimulation in both rodents and humans,20,71 it has historically
received relatively little attention as a reward center. Recent
studies, however, suggest that it integrates output from traditional
reward areas including the VTA and lateral hypothalamus.22,23 In
this context, the LS has been described as a relay node from the
hippocampus (area CA3) to the VTA, and has been suggested to
have a pivotal role in encoding context–reward associations for
cocaine.22 Notably, functional inactivation of the rostral LS
abolished cocaine CPP.23 These reports and others21,72,73 char-
acterize the LS as a brain region critically involved in coordinating
the activity of multiple reward centers and reinforce its
importance in cocaine reward.
GLP-1Rs are highly expressed in the LS and their signaling has
been shown to attenuate the locomotor response to the
psychostimulant D-amphetamine,1 to reduce cocaine CPP,14,16
and to block self-administration for cocaine in rodents.4 Therefore
it is conceivable that their signaling within the LS may modulate
cocaine CPP and reward. To support this hypothesis, a recent
study shows that GLP-1R expression in the LS controls cocaine CPP
and locomotion.3 However, the mechanism by which GLP-1R
signaling ﬁne tunes DA homeostasis and cocaine reward in the LS
remains elusive.
Cocaine, by targeting the DAT, increases extracellular DA levels,
which leads to cocaine’s behavioral actions. DAT expression level
is an important factor in determining the effects of cocaine, likely
through effects on basal DA tone. For example, extended access
to cocaine, which results in escalating cocaine intake, causes lower
expression of striatal DAT and reduced DA clearance in rats.74–78
The involvement of DAT expression in cocaine’s behavioral actions
is further supported by the ﬁnding that hyperlocomotor respon-
siveness to cocaine is signiﬁcantly enhanced in two different
mouse models expressing low levels of DAT,41,42 likely resulting
from reduced basal DAT-mediated DA uptake.41 In addition,
experiments from heterologous cell lines show that cocaine is
more potent in inhibiting DA uptake in cells expressing lower
amounts of DAT.79 Notably, a high percentage of striatal DAT (at
least 47%) needs to be occupied by cocaine in addicts before they
report subjective effects of the drug,80 implying that modulating
DAT surface expression alters the reinforcing effects of cocaine in
humans. However, it is clear to us that other mechanisms in
addition to DAT occupancy participate in the behavioral actions of
cocaine. These include altered ﬁring activity of dopaminergic
neurons and/or other mechanisms that modify DA release. These
kinds of mechanisms have been deﬁned for other drugs of abuse,
such as morphine, and may be contributing in parallel to altered
cocaine reward.81
In this study, we hypothesized that GLP-1R signaling controls, at
least in part, cocaine actions by regulating DAT expression/
function in the LS. We ﬁnd that GLP-1R agonism enhances
membrane expression of DAT. This increase translates into an
increase in transport capacity, and is paralleled by reduced ability
of cocaine to increase extracellular DA levels. Our data suggest
that increasing the amount of DAT expressed at the cell surface
may reduce the extent to which cocaine is effective at increasing
extracellular DA within the LS. These data offer an additional
mechanism for GLP-1R signaling regulation of the reinforcing and
rewarding properties of cocaine without precluding the possibility
that GLP-1R signaling may also affect DA release and ﬁring
properties of VTA neurons.
Here we ﬁnd that stimulating the GLP-1R through administra-
tion of Ex-4 in a therapeutically relevant manner (systemic
administration) reduces septal 2-AG levels. One possibility is that
the decrease in 2-AG is due to GLP-1R-mediated stimulation of
PI3K,82 or inhibition of PTEN,83 which will decrease the levels of
plasma membrane PIP2, one of the precursors for 2-AG
synthesis.84 We show that in the LS GLP-1R is located post-
synaptically. Indeed, 2-AG diffuses across synapses. Therefore, we
believe that this loss of 2-AG is causal for the observed decrease in
LS AA content as AA is primarily produced in the brain through
the presynaptic conversion from 2-AG.50 This reduction is
important as AA has been shown to inhibit DA uptake in ex vivo
and in vitro preparations,51–53 and that psychostimulants such as
amphetamine cause release of AA by activation of PLA2.
85
Consistent with AA-mediated inhibition of septal DA uptake, we
show that GLP-1R-mediated reduction in AA signaling is
associated with an increase in DA uptake in LS slices. This
increase in DAT function stems at least in part from augmented
DAT surface expression, pointing to DAT trafﬁcking as the
underlying mechanism by which GLP-1R signaling and AA levels
controls DA homeostasis in the LS, as depicted by our schematic
model (Supplementary Figure 5).
Of note, AA is known to facilitate a pro-inﬂammatory state in
the brain;86 GLP-1 analogs, on the other hand, possess both anti-
inﬂammatory and neuroprotective effects.58,87,88 GLP-1R stimula-
tion has demonstrated positive effects in rodent models of
Alzheimer’s disease as well as Parkinson’s disease (a degenerative
disorder of dopaminergic neurons).88–90 Furthermore, psychosti-
mulants themselves enhance AA levels and may exacerbate
oxidative stress in the brain,55–57,85 possibly increasing the levels
of harmful AA metabolites. On the basis of our ﬁndings, GLP-1R
signaling may oppose the effects of psychostimulants by affecting
levels of AA as well as oxidative stress.
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In this study, we provide biochemical and functional evidence
supporting the notion that AA regulates DAT function by
regulating DAT trafﬁcking. We believe that the increase in DAT
surface expression promoted by GLP-1R signaling represents a
mechanism by which this neuropeptide controls both cocaine-
induced increase in LS DA as well as cocaine actions. This AA-
mediated mechanism is enhanced by peroxidation of AA leading
to the formation of AA metabolites such as γ-KA. The treatment of
hDAT cells with AA under conditions favoring lipid peroxidation
signiﬁcantly decreased DAT surface expression and transport
capacity; the latter effect was also demonstrated with synthetic
isoketals. These results are consistent with the known ability of
isoketals to impair the function of plasma membrane proteins.91
Interestingly, AA alone was also able to signiﬁcantly reduce DAT
function. However, this reduction was smaller than that obtained
under conditions favoring lipid peroxidation or in the presence of
isoketals. These results provide a mechanism for the results
reported by Chen et al.52 and Zhang and Reith,53 wherein the
activity of DAT expressed in heterologous systems was reduced by
AA.52,53 They also mechanistically support the notion that GLP-1R
signaling regulates DA homeostasis in the LS by decreasing AA
levels. How exactly AA and its metabolites control DAT function
and trafﬁcking remains elusive. However, we hypothesize that
covalent interactions of AA metabolites with speciﬁc lysine
residues on the DAT support these actions.59 Notably, we were
able to demonstrate a physical interaction between γ-KA and DAT
by immunoprecipitation.
In summary, we have shown that GLP-1R agonism increases DAT
function and membrane expression, decreases cocaine-induced
increases in extracellular DA, and reduces endocannabinoid and AA
Figure 5. Synthetic isoketals form adducts with human dopamine transporter (hDAT) and decrease its function. (a) Immunoblots with anti-γ-
KA protein adduct and anti-DAT antibodies using green ﬂuorescent protein (GFP)-DAT immunoprecipitates from hDAT cells treated with
synthetic isoketals (1 μM) for 1 h at 37 °C. (b) Quantiﬁcation of immunoprecipitates as a ratio of γ-KA:DAT. Each value represents mean± s.e.m.
of ⩾ four independent experiments (t(6)= 3.94; **Po0.01 by Student’s t-test; n= 4). (c) Uptake of [3H]DA in hDAT cells treated with vehicle
(open circles) or with 1 μM synthetic isoketals (gray triangles) for 1 h at 37 °C. The kinetic parameters (d) Vmax and (e) Km were obtained from
the Michaelis–Menten ﬁt to [3H]DA uptake. Each value represents mean± s.e.m. of three independent experiments (Vmax: t(4)= 4.21; *Po0.05
by Student’s t-test; n= 3; Km: t(4)= 0.88; *P= 0.43 by Student’s t-test). (f) Inﬂux of [3H]DA in hDAT cells pretreated with salicylamine (0.5 mM)
and then treated with vehicle (open circles, 0.1% ethanol in Krebs–Henseleit buffer), Fe+3/Asc (open triangles) or with 40 μM AA for 1 h at 37 °C
in the absence (gray squares) or presence of Fe+3/Asc (gray triangles). The kinetic parameters (g) Vmax and (h) Km were obtained from the
Michaelis–Menten ﬁt to the inﬂux of [3H]DA. Each value represents mean± s.e.m. of ⩾ three independent experiments. No signiﬁcant
differences were observed between the groups. The statistical analysis was performed with analysis of variance. AA, arachidonic acid; Veh,
vehicle.
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signaling in the LS. This decrease is important as cocaine has been
shown to increase 2-AG tone in the brain.92 This suggests that
other brain centers targeted by cocaine and expressing the GLP-1R,
albeit at lower levels, may exhibit a similar mechanism of reward
modulation. These brain regions include the nucleus accumbens
and VTA, which have been identiﬁed as targets of Ex-4 actions on
brain reward.11–13,93,94 Nevertheless, this mechanism has still to be
validated outside the LS. Our study points to septal GLP-1R as a
potential novel target for the treatment of drug abuse. Targeting
GLP-1R signaling represents an enormous translational opportunity
as GLP-1 analogs are already available for clinical use.
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